<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994665</url>
  </required_header>
  <id_info>
    <org_study_id>CHD21-0032</org_study_id>
    <nct_id>NCT04994665</nct_id>
  </id_info>
  <brief_title>Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy</brief_title>
  <acronym>Sleevepexie</acronym>
  <official_title>Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess impact of omentopexy on de novo gastro-oesophageal reflux&#xD;
      disease (GERD) after sleeve gastrectomy.&#xD;
&#xD;
      This will be assess 2 years postoperatively. This study is a prospective, multicentric,&#xD;
      randomized trial. Five hundred twenty six patients should be included with 263 in each arm.&#xD;
      First arm will include patients who have a sleeve gastrectomy. The second arm will include&#xD;
      patients who have sleeve gastrectomy with omentopexy.&#xD;
&#xD;
      Two years after surgery , it will be collected a CARLSSON score and BAROS score (quality of&#xD;
      life).&#xD;
&#xD;
      The main objective is to show that omentopexy decreases the rate of de novo GERD after sleeve&#xD;
      gastrectomy at 2 years postoperatively without the use of Proton-Pump Inhibitors (PPIs)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate de novo GERD of patient benefited from sleeve gastrectomy with omentopexy versus sleeve gastrectomy alone</measure>
    <time_frame>2 years postoperatively</time_frame>
    <description>Presence of de novo GERD defined by a clinical score of CARLSSON &gt;= 4 and/or the use of a PPIs treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">526</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>realization of a sleeve gastrectomy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sleeve gastrectomy with omentopexy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>realization of a sleeve gastrectomy followed by an omentopexy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sleeve gastrectomy</intervention_name>
    <description>The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed</description>
    <arm_group_label>Sleeve gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sleeve gastrectomy with omentopexy</intervention_name>
    <description>After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature</description>
    <arm_group_label>sleeve gastrectomy with omentopexy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 years old,&#xD;
&#xD;
          -  Patient to be operated in first intention of a sleeve gastrectomy&#xD;
&#xD;
          -  Initial BMI between 35Kg/m² and 40 Kg/m² associated with an obesity-related&#xD;
             comorbidity (hypertension, obstructive sleep apnea syndrome, type II diabetes, early&#xD;
             osteoarthritis authenticated by a rheumatologist or an orthopedist, dyslipidemia,&#xD;
             hepatic steatosis) OR initial BMI ≥ 40 Kg/m².&#xD;
&#xD;
          -  Multidisciplinary follow-up of at least 6 months before surgery&#xD;
&#xD;
          -  Validation of the surgical intervention in a multidisciplinary consultation meeting&#xD;
&#xD;
          -  Certificate of no contraindication by a psychiatrist&#xD;
&#xD;
          -  Patient who has the capacity to understand the protocol and has given consent to&#xD;
             participate in the research,&#xD;
&#xD;
          -  Patient with social security coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eating disorder or mental disorder&#xD;
&#xD;
          -  Misunderstanding of the protocol&#xD;
&#xD;
          -  Psychiatric contraindication&#xD;
&#xD;
          -  Initial BMI &lt;35Kg/m².&#xD;
&#xD;
          -  Initial BMI between 35Kg/m² and 40 Kg/m² without comorbidities.&#xD;
&#xD;
          -  Esophagitis of grade B and above on the Oeso-Gastro-Duodenal Fibroscopy&#xD;
&#xD;
          -  CARLSSON score (score ≥ 4) preoperatively&#xD;
&#xD;
          -  Presence of a Proton-Pump Inhibitors treatment&#xD;
&#xD;
          -  Patient to have a 2-stage surgery (first sleeve gastrectomy then gastric bypass or&#xD;
             Single Anastomosis Duodeno-Ileal bypass)&#xD;
&#xD;
          -  Patient participating in another interventional clinical research protocol involving a&#xD;
             drug or medical device&#xD;
&#xD;
          -  Patient who are pregnant, breastfeeding, or who have the potential to become pregnant&#xD;
             without effective contraception at the time of inclusion and up to 24 months after&#xD;
             surgery&#xD;
&#xD;
          -  Patient under guardianship, curators or legal protection,P&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emeric Abet, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnès Dorion</last_name>
    <phone>251446380</phone>
    <phone_ext>+33</phone_ext>
    <email>agnes.dorion@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Emeric ABET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Claire BLANCHARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Damien BERGEAT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Santé Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Antoine SINA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleeve gastrectomy</keyword>
  <keyword>omentopexy</keyword>
  <keyword>gastro-oesophageal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

